Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Kevin Bray,1,2 Hsin-Yi Chen,1,2 Cristina M. Karp,1 Michael May,1 Shridar Ganesan,1,3 Vassiliki Karantzalos-Wadsworth,1,3 Robert S. DiPaola1,2 and Eileen White1,2

1The Cancer Institute of New Jersey, New Brunswick, New Jersey; 2Rutgers University, Piscataway, New Jersey; and 3Division of Medical Oncology, Department of Internal Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School

Abstract
Apoptosis resistance is a hallmark of cancer linked to disease progression and treatment resistance, which has led to the development of anticancer therapeutics that restore apoptotic function. Antiapoptotic Bcl-2 is frequently overexpressed in refractory prostate cancer and increased following standard hormonal therapy and chemotherapy; however, the rationally designed Bcl-2 antagonist, ABT-737, has not shown single agent apoptosis-promoting activity against human prostate cancer cell lines. This is likely due to the coordinate expression of antiapoptotic, Bcl-2–related Mcl-1 that is not targeted by ABT-737. We developed a mouse model for prostate cancer in which apoptosis resistance and tumorigenesis were conferred by Bcl-2 expression. Combining ABT-737 with agents that target Mcl-1 sensitized prostate cancer cell lines with an apoptotic block to cell death in vitro. In mice in vivo, ABT-737 showed single agent efficacy in prostate tumor allografts in which tumor cells are under hypoxic stress. In human prostate cancer tissue, examined using a novel tumor explant system designated Tumor Tissue Assessment for Response to Chemotherapy, combination chemotherapy promoted efficient apoptosis. Thus, rational targeting of both the Bcl-2 and Mcl-1 mechanisms of apoptosis resistance may be therapeutically advantageous for advanced prostate cancer.

(Mol Cancer Res 2009;7(9):1487–96)

Introduction
Advanced prostate cancer is only temporarily controlled by either androgen ablation therapy or chemotherapy due to mechanisms of drug resistance (1). Progression towards drug resistance can be achieved through the inactivation of apoptosis, and is generally considered to be a hallmark of cancer (2). Understanding these drug resistance mechanisms allows for the identification of ways to therapeutically reactivate the death response and a means to develop clinical trials to treat the disease (3, 4).

Apoptosis is a highly controlled process activated in response to specific stimuli, cellular damage, stress, and chemotherapy leading to cellular dismantling within membrane-enclosed vesicles that are engulfed by phagocytes (5–7). Bcl-2 family members are key regulators in the apoptotic pathway (5, 7). Bcl-2 family members fall into three classes based on conserved homology domains (BH1–4): antiapoptotic multidomain (Bcl-2, Bcl-xL, Mcl-1, and Bfl-1/A1), proapoptotic multidomain (Bax and Bak), and BH3-only (Bid, Bim, Puma, and Noxa) proteins. Multidomain Bcl-2–like proteins contain a large hydrophobic cleft that is a receptor for the BH3 α-helix of essential apoptosis effectors Bax and Bak, which neutralizes their proapoptotic function (5, 7, 8). The BH3 of BH3-only proteins disrupts Bax and Bak sequestration and may also directly activate Bax and Bak. Once activated, Bax and Bak oligomerize in the mitochondrial outer membrane, releasing cytochrome c, which stimulates the apoptosome and promotes activation of the cysteine protease caspase-9 (6). Subsequent effector caspase-3 activation leads to the cleavage of cellular substrates and apoptotic cell death. Apoptosis is an effective cell-intrinsic tumor suppression mechanism to limit tumor initiation and progression, and is also a critical mechanism to facilitate tumor regression in cancer therapy.

Prostate cancer commonly exhibits high levels of Bcl-2 expression in refractory, advanced disease that contributes to defective apoptosis associated with poor prognosis (9). Modulating Bcl-2 in patients with prostate cancer is limited due to few therapeutic options (10–12). Mechanistic insight into apoptosis regulation has led to novel therapeutic approaches. For example, the hydrophobic cleft of antiapoptotic Bcl-2–like proteins has been targeted with small molecules as the basis for the BH3-mimetic class of Bcl-2–inhibitory, proapoptotic anticancer drugs (3). The Bcl-2 antagonist and BH3-mimetic ABT-737 binds with high affinity to the hydrophobic cleft and BH3 receptor region of Bcl-2, Bcl-xL, and Bcl-w, but not to the less homologous Bcl-2–related protein Mcl-1. This ABT-737/Bcl-2 interaction antagonizes the interaction of Bcl-2 with the BH3 domain of proapoptotic proteins, neutralizing Bcl-2. Although ABT-737 shows single agent activity promoting apoptosis in human small cell lung cancer and lymphoma cell lines in vitro and in tumor xenografts, apoptosis is not triggered in most human cancer cell lines (13–16). Expression of Mcl-1 that is not targeted by ABT-737 may explain the resistance of prostate and other cancer cell lines to apoptosis.

One means to inhibit Mcl-1, which is necessary but not sufficient for apoptosis, is activation of the DNA damage response...
pathway that targets Mcl-1 for proteasome-mediated degradation (17, 18). Chemotherapeutic agents that directly induce DNA damage (etoposide and cisplatin) are expected to induce Mcl-1 elimination that occurs by a p53-independent mechanism (18, 19). Furthermore, paclitaxel, which targets microtubules and induces Bim accumulation (antagonizing both Bcl-2 and Mcl-1; ref. 20), might promote apoptosis. Although taxanes and platinum agents have been used to treat prostate cancer, they are not effective against advanced disease, perhaps due to high levels of Bcl-2 which may inhibit apoptosis even when Mcl-1 is eliminated. Mcl-1 expression is known to increase during prostate cancer progression (21), indicating that it could be a potential clinical target. Thus, simultaneously targeting Bcl-2 and Mcl-1 could be a rational regimen in disease treatment.

Here, we report that paclitaxel, etoposide, and cisplatin act synergistically with the Bcl-2 antagonist ABT-737 to induce apoptosis in a mouse model for prostate cancer. The combination of ABT-737 with paclitaxel, etoposide, or cisplatin resulted in down-regulation of Mcl-1, cytochrome c release, and caspase-3 activation in immortalized mouse prostate epithelial cell lines that possess an apoptosis defect and are rendered tumorigenic through Bcl-2 expression. Surprisingly, ABT-737 promoted tumor regression as a single agent in immortalized mouse prostate tumor allografts, in which in vivo stress may provide signals to induce BH3-only proteins to antagonize Mcl-1. Importantly, cisplatin and ABT-737 act synergistically to induce apoptosis in a novel tumor explant system we have designated Tumor Tissue Assessment for Response to...
Chemotherapy (TTARC). Taken together, these preclinical data support the development of therapy with a platinum agent in combination with a Bcl-2 inhibitor in the treatment of prostate cancer.

**Results**

**A Novel Mouse Model for Prostate Cancer**

Most prostate cancers are adenocarcinomas arising from prostate epithelial cells (22). We developed a novel mouse model for prostate epithelial tumor progression and treatment responsiveness (23, 24). Primary prostate epithelial cells were isolated from male C57B/6 mice and immortalized through the expression of E1A and a dominant-negative p53 to inactivate the Rb and p53 pathways (Fig. 1A). Eight independent immortal mouse prostate epithelial cell lines (iMPEC) were generated and characterized. Six iMPEC cell lines (2-7) formed fusion sheets, characteristic of epithelial cells in culture, whereas two (1 and 8) had fewer cell-cell junctions and a more mesenchymal morphology (Fig. 1A). All iMPECs express E1A and dominant-negative p53, as well as the androgen receptor, the prostate-specific homeobox protein Nkx3.1, and the epithelial cell marker β-catenin (Fig. 1B). Consistent with their morphologic appearance (Fig. 1A), iMPEC cell lines 2 to 7 expressed the luminal epithelial cell marker cytokeratin 8/18, whereas iMPEC cell lines 1 and 8 expressed the basal cell marker vimentin (Fig. 1B). This suggests that two prostate epithelial cell types, luminal and basal cells, were immortalized.

To evaluate apoptosis pathways, the endogenous expression of Bcl-2 family members was examined. All iMPECs express the antiapoptotic Bcl-2, Bcl-xL, Mcl-1, and proapoptotic Bax and Bak (Fig. 1C). iMPECs also express variable levels of Bim (Figs. 1C and 2B). iMPECs were poorly and clonally tumorigenic, indicating that inactivating the Rb and p53 pathways in mouse prostate epithelial cells was insufficient for tumorigenesis (Fig. 1D). Previously established work has shown that tumors which take longer than 2 months to appear require an additional genetic event to enable tumorigenesis (23-25). Mutations in ras genes (H-ras, K-ras, and N-ras) are associated with human prostate tumor progression (26-28), and H-Ras activation blocks apoptosis rendering iBMKs and iMMECs highly tumorigenic (20, 29, 30). As such, iMPEC-7...
was engineered to express activated H-Ras^V12 (Supplementary Fig. S1), which conferred tumorigenicity (Fig. 1D).

**iMPECs Have an Intact p53-Independent Apoptotic Response**

Because iMPECs express Bim (Figs. 1C and 2B), which is induced by and is a determinant of apoptotic response to taxanes (20, 31), we examined iMPECs for apoptosis in response to paclitaxel. Paclitaxel (at 300 nmol/L and 1 μmol/L) caused loss of viability (Fig. 2A) accompanied by robust Bim induction and caspase-3 activation (Fig. 2B), indicating an intact p53-independent apoptotic response in iMPECs. iMPECs show some variability; however, all responded to paclitaxel with Bim induction and apoptosis. As Bim is a potent Bcl-2 antagonist (32, 33), and up-regulation of Bcl-2 is implicated in prostate cancer progression (34), this supports a prominent role of the Bim-Bcl-2 axis in the apoptotic response of prostate epithelial cells. This intact p53-independent apoptotic response may be responsible for defective tumorigenesis (Fig. 1D). To test this, iMPEC-7 was engineered to express human Bcl-2 (hBcl-2; Fig. 2C), which substantially blocks apoptosis (see below). Bcl-2 expression promoted tumorigenesis (Fig. 2D), although to a lesser extent than H-Ras^V12 (Fig. 1D). Bcl-2–expressing iMPEC tumors were carcinomas with well-vascularized sheets of epithelial cells and isolated areas of necrosis. Additionally, tumor tissue invaded the skeletal muscle (Fig. 2D, inset).

![FIGURE 3. ABT-737 acts synergistically with paclitaxel to induce apoptosis. A. MTT assay of iMPEC-7_pcDNA3 (top) and iMPEC-7_Bcl-2 (bottom). iMPEC-7_pcDNA3 was killed with lower concentrations of ABT-737/paclitaxel than iMPEC-7_Bcl-2 (arrows). Viabilities are relative to time 0. B. Indirect immunofluorescence for cytochrome c release. iMPEC-7_pcDNA3 and iMPEC-7_Bcl-2 were treated with 300 nmol/L of paclitaxel and 10 μmol/L of ABT-737 for 2 d. Arrows, cells with released cytochrome c. Percentage of cytochrome c release (bottom left corner of each image). Bar, 10 μm. C. iMPEC-7_Bcl-2 showed caspase-3 activation in response to 10 μmol/L of ABT-737 and 300 nmol/L of paclitaxel (box). D. Quantitation of activated caspase-3. ABT-737/ paclitaxel combination induced high levels of active caspase-3 at 2 d. Bars, SD based on three independent experiments.](mcr.aacrjournals.org)
ABT-737 Acts Synergistically with Paclitaxel to Induce Apoptosis

Because agents that target microtubules, such as the taxane docetaxel, have been clinically active against prostate cancer and can improve survival with temporary duration of response, we examined the apoptotic response of Bcl-2–expressing iMPECs to taxane chemotherapy. Bcl-2 expression conferred resistance to the taxane paclitaxel (Fig. 3). Accordingly, we sought to determine if ABT-737 could act synergistically with paclitaxel to induce apoptosis. Paclitaxel (300 nmol/L) in combination with the less active enantiomer control for ABT-737 had no effect on cell viability in iMPECs with endogenous or...
hBcl-2 expression (Fig. 3A), whereas 1 μmol/L of paclitaxel alone or with the enantiomer resulted in the cell death of IMPECs with endogenous Bcl-2 expression. In contrast, 0.1 μmol/L of ABT-737 in combination with 300 nmol/L of paclitaxel was sufficient to kill 70% of IMPECs with endogenous Bcl-2 in 3 days (Fig. 3A, top). hBcl-2–expressing IMPECs required 10 μmol/L of ABT-737 with 300 nmol/L of paclitaxel to induce similar levels of apoptosis induction (Fig. 3A, bottom). The ABT-737/paclitaxel combination induced cytochrome c release and caspase-3 activation (Fig. 3B-D; Supplementary Fig. S2). IMPECs with endogenous Bcl-2 had higher levels of cytochrome c release and activated caspase-3 when compared with hBcl-2–expressing IMPECs. Combination of paclitaxel with the enantiomer resulted in some cytochrome c release and caspase-3 activation, but overall levels were significantly higher with the ABT-737/paclitaxel combination (Fig. 3B-D; Supplementary Fig. S2). This showed that a taxane could act synergistically with ABT-737 to induce apoptosis in prostate cancer cell lines, thereby overcoming an apoptosis block conferred by hBcl-2.

**ABT-737 Restores Apoptosis in Combination with DNA-Damaging Agents**

We next tested whether ABT-737 in combination with DNA-damaging agents that target the antiapoptotic Mcl-1 protein could overcome an apoptotic block conferred by hBcl-2. The viability of IMPECs was assessed with ABT-737, or the enantiomer, with or without cisplatin, an alkylating agent that forms DNA adducts or etoposide, a topoisomerase II inhibitor that induces DNA breaks. The combination of 12.5 μmol/L of cisplatin and 0.1 μmol/L of ABT-737 effectively killed 90% of IMPECs with endogenous Bcl-2 (Fig. 4A, top). Cisplatin (12.5 μmol/L) induced a 50% reduction in viability within 3 days in IMPECs with endogenous Bcl-2, but was unable to kill hBcl-2–expressing IMPECs, whereas a combination of 25 μmol/L of cisplatin and 10 μmol/L of ABT-737 was required to kill 90% of IMPECs expressing hBcl-2 (Fig. 4A). This showed that hBcl-2 expression produced resistance to cisplatin-mediated apoptosis, and that ABT-737 was not an effective inducer of cell death as a single agent. As expected, cisplatin treatment down-regulated the levels of Mcl-1 over 3 days in both IMPECs with endogenous Bcl-2 and those with hBcl-2 (Fig. 4C). ABT-737/cisplatin combination resulted in cytochrome c release and activation of caspase-3, even with hBcl-2 expression (Fig. 4B-D; Supplementary Fig. S3). This showed that ABT-737, when used in combination with DNA-damaging agents, effectively induced apoptosis in cells normally refractory to cell death. Interestingly, Bcl-2 levels were down-regulated in response to higher concentrations of ABT-737 and cisplatin (Fig. 4C). Similar results were achieved when etoposide was used in combination with ABT-737, suggesting a general synergy between DNA damage and Bcl-2 antagonism (Supplementary Fig. S4).

**ABT-737 Promotes the Regression of Prostate Tumor Allografts**

Because ABT-737 and cisplatin displayed synergy in vitro and could overcome apoptosis resistance conferred by Bcl-2, we investigated the response of mouse prostate tumor allografts to combination therapy. IMPECs expressing hBcl-2 were injected s.c. into mice and allowed to form tumors. ABT-737 was injected i.p. at a dose of 100 mg/kg/d for 14 consecutive days. Cisplatin was injected i.p. at a dose of 2.5 mg/kg on days 1 and 8. Vehicle and cisplatin injections had no effect on tumor growth, whereas ABT-737 and the ABT-737/cisplatin combination prevented tumor growth and promoted tumor regression (Fig. 5A and B). Thus, the response to Bcl-2 inhibition can be different in vivo compared with in vitro.

**ABT-737 and Cisplatin Promote Apoptosis in Human Prostate Tumor Tissue Explants**

The conflicting requirement of cisplatin for synergy with a Bcl-2 antagonist for apoptosis activation in vitro versus in vivo raised the question as to what to expect for therapeutic apoptosis...
modulation in human prostate cancer therapy. To assess the potential effectiveness of chemotherapy in patients with prostate cancer, in which access to tumor tissue during treatment is limited, we developed a novel tumor explant system designated TTARC wherein tumor tissue is assessed for apoptotic response to therapy *ex vivo*. Briefly, human prostatectomy samples were obtained immediately following surgery, and sectioned to generate successive adjacent tumor tissue slices from the same tumor (Fig. 6A). Tissue sections were left untreated or treated with ABT-737, the enantiomer, cisplatin, or the combination of cisplatin and ABT-737 or the enantiomer. Five human prostate tumors were analyzed by TTARC, and remarkably, tissue remained healthy for at least 16 hours, as indicated by H&E staining of healthy epithelial cells in the glands with intact stroma (Fig. 6B) that was similar to sections fixed at the start of the incubation (time 0). Treatment duration varied from 16 to 48 hours and was compared with time 0. Two different concentrations of ABT-737 were tested (1 and 10 μmol/L). Although there was some variability in the integrity of the samples and in the levels of apoptosis induced, it was clear that the combination of ABT-737 and cisplatin was the most effective apoptosis inducer. The control enantiomer of ABT-737 induced minimal levels of apoptosis alone or in combination with cisplatin (Fig. 6; data not shown). Incubation with either 12.5 μmol/L of cisplatin or 10 μmol/L of ABT-737 resulted in little or no induction of apoptosis (Fig. 6B; Table 1). In contrast, the same concentrations of ABT-737 in combination with cisplatin induced significantly higher levels of activated caspase-3 and obvious signs of epithelial tissue degradation, i.e., elimination of tumor cells from the tissue (Fig. 6B; Table 1). Assessing active caspase-3 at specific times of treatment provides a snapshot of apoptosis activity and the enhanced tissue degradation in combination drug–treated tissues likely reflects accelerated apoptosis and possible necrotic cell death. This indicated that combination of a Bcl-2 antagonist with cisplatin could overcome apoptosis resistance in human prostate tumor tissue and provides preclinical justification for therapeutic treatment development.

**Discussion**

As in many cancers, defective signaling of apoptosis likely contributes to treatment failure, and in advanced prostate cancer, is associated with high levels of Bcl-2 (9). However, in most cancers, it seems unlikely that targeting Bcl-2 alone will be sufficient for apoptosis induction due to functionally
Bol indicate the level of positive staining.

Similarly, targeting only McI-1 is also insufficient for apoptosis induction in cancer cell lines (17, 18, 38). Strategies to activate apoptosis through modulation of Bcl-2 family members may require neutralization of multiple antiapoptotic Bcl-2 proteins (8, 38).

Proper targeting will depend on knowing which Bcl-2–related proteins are expressed and are essential for blocking apoptosis in particular cancers. The BH3-mimetic ABT-737 (15) and the orally available relative ABT-263 (39) neutralize multiple Bcl-2–related proteins (Bcl-2, Bcl-xL, and Bcl-w) but not McI-1 (14, 37, 39). ABT-737 as a single agent is insufficient to induce apoptosis in most cancer cell lines and xenografts (15, 37) as well as in normal tissues with the exception of platelets, which are particularly reliant on Bcl-xL for survival (40, 41). As such, a BH3 mimic that neutralizes McI-1, for example, would be a valuable strategy to obtain synergy with ABT-737 for apoptosis induction. Alternatively, inhibition of McI-1 by indirect means such as DNA damage should achieve similar results. Indeed, synergy between ABT-737 and a platinum agent has been reported to promote apoptosis in ovarian cancer cell lines in vitro (42), as we have reported here in prostate cancer cell lines.

Upstream of Bcl-2 and McI-1, the proapoptotic BH3-only protein Bim is an epithelial tumor suppressor that is dramatically up-regulated in response to taxane-based chemotherapy (20).

We observed similar Bim induction associated with caspase-3 activation and apoptosis by paclitaxel in IMPECs. By virtue of its broad binding specificity, Bim may be critically important for modulating apoptosis. Indeed, Bim is a tumor suppressor in Myc-induced lymphomas and promotes apoptosis in conjunction with imatinib in human leukemia cell lines (43). However, high levels of Bcl-2 expression are sufficient to block apoptosis and render IMPECs and other cell lines tumorigenic, and taxane-mediated Bim induction is insufficient to overcome this apoptotic block conferred by Bcl-2. Moreover, antagonizing Bcl-2 with ABT-737 was insufficient to trigger apoptosis. In contrast, combining ABT-737 with a taxane or DNA-damaging agent caused a dramatic induction of apoptosis in prostate cancer cell lines in vitro, suggesting the possible utility of these combinations for prostate cancer therapy (Fig. 6C).

Surprisingly, ABT-737 displayed single-agent efficacy in mouse prostate tumor allografts. Thus, the apoptotic response can vary greatly between in vitro and in vivo situations. In contrast to growth in vitro, tumors in vivo are subjected to hypoxia and the induction of BH3-only proteins such as Puma and activation of Bim-mediated Bax and Bak-dependent apoptosis and tumor repression (20). Because Puma and Bim are proapoptotic BH3-only proteins with broad-spectrum–binding activity toward antiapoptotic Bcl-2 family members including McI-1, the in vivo environment may provide signals to induce McI-1 antagonists, explaining why ABT-737 displayed single-agent efficacy. Alternatively, subcutaneously grown mouse prostate tumors are very distinct from spontaneous human prostate cancers with respect to stroma and microenvironment. Subcutaneous tumors have markedly less stroma and when subjected to TTARC, undergo accelerated disintegration when compared with human prostate cancer tissue. These dramatic differences between apoptotic responses of tumor cells in vitro and in vivo raised questions about the predictability of patient responses.

Although mouse models are tremendously valuable for functional validation of mechanisms involved in cancer modulation, in many cases, they fail to accurately represent the diversity and complexity found in human cancers. It may be that the substantial stromal components and natural microenvironment in the prostate helps to maintain tissue integrity (including tumor tissue) which influences responses to chemotherapy and supports survival. This is yet another mechanism by which tumors grown subcutaneously in a mouse may respond differently from tumors spontaneously arising in tissues. Effective drug treatments in xenograft models often have little efficacy in the clinic. The outcome of such experiments is dependent on many variables, such as site of implantation, growth properties of xenografts, tumor size when treatment is initiated, agent formulation, route of administration and dose, and selected end point for assessing activity (44-46). In contrast, mechanistic assessment and validation of cancer treatment in solid tumor–bearing humans can be problematic due to limited or insufficient access to tumor tissue, disease diversity, and lack of molecular characterization of individual tumors. In human prostate cancer, the limited access to tumor tissue during treatment precludes determination that a particular treatment is effective by the expected mechanism. Assessment of surrogate markers as indicators of mechanistic validation is a common alternative but is not ideal.
as it is often not clear if normal tissues reflect the properties of tumors often derived from completely different tissue types. The means to bridge the gap between mouse cancer models and human cancers, both with their inherent strengths and weaknesses, has been a major issue in the field of cancer research.

To bridge this gap, we have developed an ex vivo tumor tissue explant system (TTARC). The concept was to take cancer-containing prostatectomy samples that retain tumor tissue and stroma intact in thin tissue slices that can be incubated in cell culture media for short periods of time during which the apoptotic response (active caspase-3) to chemotherapy could be assessed. Remarkably, the tissue remained healthy as assessed by histologic appearance. Tumor tissue disruption and isolation of tumor cells typically results in a poor rate of cell survival, but retaining the tumor cells, associated stroma, and microenvironment intact in tissue slices apparently provided a substantial survival advantage. Similar results have been obtained using the TTARC system with human breast and ovarian cancer samples (data not shown). Multiple tissue slices were obtained from each prostatectomy sample which enabled the analysis of replicates and allowed for time course dose-response and drug combination assessment that would have otherwise been difficult or impossible to assess in human cancers by available means.

When evaluated for apoptosis induction by cisplatin, ABT-737 alone or in combination, the combination produced a striking activation of caspase-3 and cell death. These findings were reproducible in multiple prostatectomy samples and the tumor cells within the tissue seemed to be more susceptible to apoptosis activation compared with the neighboring normal prostate epithelia. The different response of tumor allografts (and potentially xenografts) to ABT-737 suggests that apoptotic therapeutic response is highly context-dependent. Spontaneous tumors that coevolve with stroma and tissue microenvironment may be under less stress compared with transplanted tumor cells and this may be reflected in altered response to chemotherapy. This suggests that improving the assessment of the response to chemotherapy of human tumors may be advantageous. The development of TTARC enables preclinical assessment of chemotherapeutics in human cancer prior to the treatment of patients. This will become increasingly valuable as a preclinical justification for new clinical trials. In future studies, it will be important to correlate the results of TTARC with response to chemotherapy and clinical outcome. As such, combining cisplatin and perhaps paclitaxel with the BH3-mimetic ABT-737 may be a worthwhile approach to prostate cancer therapy.

Materials and Methods

Generation of Cell Lines

Prostates from 6-wk-old male C57Bl/6 mice were used to generate immortalized mouse prostate epithelial cells as previously described (23, 24, 47). Stable cell lines expressing H-RasV12, hBcl-2, or vector control were derived through electroporation of pcDNA3.1-hBcl-2 (48), pCGN-H-RasV12, or pcDNA3.1 (Invitrogen) followed by geneticin (Life Technologies-Invitrogen) selection.

Chemicals and 3-(4,5-Dimethylthiazol-2-yl)2,5-Diphenyltetrazolium Bromide Assay

3-(4,5-Dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT assay) and cisplatin were from Sigma, etoposide and paclitaxel were from Calbiochem, and ABT-737 and control enantiomer were from Abbott Laboratories. ABT-737 and its enantiomer were prepared in DMSO and stored at −20°C.

Western Blotting, Immunofluorescence, and Immunohistochemistry

Western blotting and immunofluorescence was done as previously described (17, 49, 50). For cytometric detection, cells were fixed in 4% paraformaldehyde (Sigma), and for caspase-3 immunofluorescence, cells were fixed with Formaldehyde-fresh (Fisher Scientific) for 15 min at room temperature.

Tumor Formation and Chemotherapy

Tumor formation and volume in nude mice was done as previously described (24). Tumor formation assays were done using Institutional Animal Care and Use–approved protocols. Tumors for histology were fixed with Formaldehyde-fresh (Fisher Scientific). For chemotherapeutic experiments, iMPEC-7_Bcl-2 tumors reached 80 to 90 mm3, mice were sorted randomly into groups of six and subjected to i.p. injection of vehicle, cisplatin (2.5 mg/kg on days 1 and 8), ABT-737 (100 mg/kg/d for 14 d), or cisplatin in combination with ABT-737. For i.p. injection, ABT-737 was prepared in 30% propylene glycol, 5% Tween 20, and 65% D5W (5% dextrose in water). Cisplatin was prepared in PBS.

The TTARC System

Human prostatectomy samples were obtained from the Tissue Analytical Services at The Cancer Institute of New Jersey immediately following surgery. Vibratome-sliced samples (200 μm) were placed on gel foam/surgifoam (Ethicon) in DMEM plus 10% fetal bovine serum with or without drugs. Sections were fixed in Formaldehyde-fresh (Fisher Scientific) for 1 h and transferred to 70% ethanol. Immunohistochemistry and histology were done as described (50). Prostate tissue sections were scored based on intensity of staining. P values were determined by assigning the number of “+” signs a numeral value, i.e., “+++” would be assigned a value of 4. These numbers were then used to calculate P values via one-way ANOVA with Bonferroni’s post-test (GraphPad Prism 4). Institutional Review Board approval was obtained for these experiments.

Disclosure of Potential Conflicts of Interest
Dr. Eileen White is a consultant for Merck, Millennium, BMS, and Chugai.

Mol Cancer Res 2009;7(9). September 2009
Downloaded from mcr.aacrjournals.org on July 11, 2017. © 2009 American Association for Cancer Research.
Acknowledgments
We thank Thomassina Sharkey for assistance with manuscript preparation; Drs. Cory Abate-Shen and Robert Evans for providing antibodies; Drs. Steven Elmore, Saul Rosenberg, and Steven Fesik at Abbott Laboratories for supplying ABT-737 and the enantioomer; the Tissue Analytical Services at The Cancer Institute of New Jersey for providing the human prostatectomy samples and tissue sectioning; and the members of the White lab for helpful advice.

References
Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Kevin Bray, Hsin-Yi Chen, Cristina M. Karp, et al.


Updated version Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-09-0166

Supplementary Material Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2009/09/15/1541-7786.MCR-09-0166.DC1

Cited articles This article cites 49 articles, 23 of which you can access for free at: http://mcr.aacrjournals.org/content/7/9/1487.full.html#ref-list-1

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at: /content/7/9/1487.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Permissions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.